AEON Biopharma, Inc. (AEON)
Automate Your Wheel Strategy on AEON
With Tiblio's Option Bot, you can configure your own wheel strategy including AEON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AEON
- Rev/Share 0.0
- Book/Share -2.8415
- PB -0.2727
- Debt/Equity -1.2894
- CurrentRatio 1.426
- ROIC 27.385
- MktCap 8761685.0
- FreeCF/Share -4.9199
- PFCF -0.4469
- PE 0.0183
- Debt/Assets 1.058
- DivYield 0
- ROE -6.7695
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 3
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
AEON Biopharma, Inc. Announces Reverse Stock Split
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that the Company's Board of Directors approved a 1-for-72 reverse stock split (the “Reverse Stock Split”) of the Company's common stock, par value $0.0001 (the “Common Stock”), to increase the selling price of the Company's Common Stock in order to maintain compliance with the requirements and policies of the NYSE American LLC (the “NYSE American”).
Read More
About AEON Biopharma, Inc. (AEON)
- IPO Date 2023-07-24
- Website http://www.aeonbiopharma.com
- Industry Biotechnology
- CEO Robert Bancroft
- Employees 5